Rubicon Research Limited
NSE: RUBICON · Pharmaceuticals · sector
₹1,490.30NSE close 2026-10-26
Key numbers
Market cap₹24,647 cr
Price₹1,490.30
52w high / low₹1,899 / ₹571
P/E84.0xSector median 27.9x
P/B19.1xSector median 2.9x
Book value₹77.9
Dividend yield0.00%Sector median 0.48%
ROE22.4%Sector median 11.7%
ROCE26.6%Sector median 12.3%
OPM23.3%Sector median 14.0%
Debt / equity0.20xSector median 0.16x
EV/EBITDA54.5xSector median 18.6x
Interest cover10.1x
Current ratio2.01x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹346 cr vs borrowings ₹259 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 10.1x in the last 12 months.
- Other income was 4% of net profit in the last 12 months.
- No dividend in the last 1 financial years.
- Price ₹1,490.30 on 2026-10-26: -21.5% from the 52-week high, +161.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,828.80 · low ₹589.85
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 412 | 476 | 514 | 534 |
| EBITDA | 94 | 108 | 119 | 129 |
| OPM % | 22.9% | 22.7% | 23.1% | 24.2% |
| Other income | 1 | 4 | 3 | 6 |
| Net profit | 54 | 73 | 77 | 85 |
| EPS (₹) | 3.49 | 4.46 | 4.66 | 5.13 |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY26 | TTM |
|---|---|---|
| Revenue | 1,754 | 1,936 |
| EBITDA | 400 | 450 |
| Net profit | 247 | 288 |
| EPS (₹) | 15.52 | 17.74 |
| Dividend / share (₹) | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | +136.7% |
Balance sheet
| ₹ cr | FY26 |
|---|---|
| Shareholders' equity | 1,289 |
| Borrowings | 259 |
| Cash & equivalents | 346 |
| Total assets | 2,327 |
| Fixed assets | 467 |
| Capital work in progress | 40 |
| Investments | 27 |
| Receivables | 509 |
| Inventory | 729 |
| Payables | 377 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY26 |
|---|---|
| Cash from operations | 205 |
| Cash from investing | -410 |
| Cash from financing | 283 |
| Capex | 229 |
| Free cash flow | -24 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY26 |
|---|---|
| ROE % | 19.1% |
| ROCE % | 23.4% |
| Debtor days | 106 |
| Inventory days | 479 |
| Payable days | 248 |
| Cash conversion cycle (days) | 337 |
| Working capital days | 176 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 51.25% |
| FIIs | 9.01% |
| DIIs | 15.72% |
| of which Mutual funds | 13.78% |
| of which Insurance | 0.16% |
| Public (non-institutions) | 24.02% |
| Quarter | Oct 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|
| Promoters % | 59.99% | 59.99% | 59.86% | 59.76% | 51.25% |
| Promoter group | % |
|---|---|
| General Atlantic Singapore Rr Pte Ltd | 27.34% |
| Surabhi Parag Sancheti | 7.91% |
| Sumant Pilgaonkar | 7.89% |
| Pratibha Sudhir Pilgaonkar | 3.89% |
| Sudhir D Pilgaonkar | 3.89% |
| Terentia Venture Partners | 0.31% |
| Parag Suganchand Sancheti | 0.02% |
| Prashant Pilgaonkar | 0.00% |
| Sheela Suganchand Sancheti | 0.00% |
| Suganchand Gendulal Sancheti | 0.00% |
| Ananya Parag Sancheti | 0.00% |
| Ira Parag Sancheti | 0.00% |
| Saloni Pilgaonkar | 0.00% |
| Kimaya Sumant Pilgaonkar | 0.00% |
| Kirit Vishanji Gala | 0.00% |
| Public holders above 1% | % |
|---|---|
| Shivanand Shankar Mankekar Huf | 13.51% |
| Kotak Midcap Fund | 4.09% |
| Hdfc Trustee Company Ltd. A/C Hdfc Balanced Advantage Fund | 3.50% |
| Amansa Investments Ltd | 3.12% |
| Motilal Oswal Small Cap Fund | 1.39% |
| Fidelity Funds - India Focus Fund | 1.23% |
| ICICI Prudential Flexi Cap Fund | 1.21% |
| Aranda Investments Pte. Ltd. | 1.19% |
| Bajaj Finserv Flexi Cap Fund | 1.11% |
| Nomura Funds Ireland Public Limited Company- Nomura Funds Ireland - India Equity Fund | 1.10% |
| Narendra Narhar Borkar | 1.07% |
| SBI Multicap Fund | 1.01% |
38,018 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| RUBICON | ₹24,647 cr | 84.0x | 19.1x | 22.4% | 26.6% | 23.3% | – | 0.00% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-08-07 | Dividend | Dividend - Rs 1.50 Per Share |
Documents
- Annual report FY26
- Annual report FY26
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceuticals: Company is into pharmaceutical formulations driven by innovation through focused research and development delivering value to customers and investors by developing, manufacturing, and marketing branded specialty and generic pharmaceutical products.
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | RUBICON |
| BSE code | 544578 |
| ISIN | INE506V01022 |
| Face value | ₹1.0 |
| Incorporated | 1999-05-06 |
| Website | www.rubicon.co.in |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.